METabolic EXplorer has submitted a filing to the FDA concerning its METEX 100% bio-based L- Methionine project. As an outcome was expected early January, a date now passed, METabolic EXplorer has contacted this administration to understand the reasons for the delay.
It appears that the FDA has all the necessary information to handle this filing and that the delay is the result of a mere administrative procedure. As such, METabolic EXplorer is confirming that the delay does not call into question the filing as a whole and that it remains confident as to the outcome expected in the very near future.
METabolic EXplorer will publish an update on the filing as soon as the FDA issues its position.
-ENDS-
About METabolic EXplorer - www.metabolic-explorer.com
METabolic EXplorer is a biological chemistry company which was incorporated in 1999. Its goal is to help industrial businesses deal with the rise in oil prices, so that they can continue their production, in a different, sustainable way.
Based on the tried and tested principle of industrial fermentation, METabolic Explorer's solutions replace today's petrochemical processes with the use of a wide range of plant-based raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (textile fibres, paints, solvents, plastics and animal feed).
METabolic EXplorer is currently focusing its alternative processes on the production of three compounds that together have an estimated, annual, end-market value of €7 billion. The company's strategy will be implemented through industrial partnerships in the shape of joint ventures and licences, as well as own-account production units.
METabolic EXplorer, based in Clermont-Ferrand, France, is listed on NYSE Euronext in Paris
(Compartment C, METEX) and is part of the CAC Small index.
Get free financial information on METabolic EXplorer by registering with:
www.metabolic-explorer.comor www.actus-finance.com
Media and individual shareholder relations ATTITUDE Corporate
Eric de Lambert
E: edelambert@attitude-corporate.com
T: +33 (0)1 4970 4341 / +33 (0)6 2529 0658
Jérôme Fabreguettes-Leib
E: jfl@actus.fr
T: +33 (0)1 7735 0436
This communication includes forward-looking information which is subject to risks and uncertainties. The potential development of the company could be substantially different from that anticipated in this press release because of the various risk factors which are described in the company's Listing Prospectus.
distributed by |